Business
Imfinzi improved EFS and OS in bladder cancer
Imfinzi improved EFS and OS in bladder cancer.
About this update from Astrazeneca Plc
[{"type":"text","content":"\n\n\n \n \n25 June 2024\n \nImfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for\nmuscle-invasive bladder cancer in NIAGARA Phase III trial\n \nFirst immunotherapy regimen before and after\nsurgery to extend survival in bladder cancer\n \nPositive high-level results from the NIAGARA Phase III trial showed AstraZeneca's Imfinzi (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus neoadjuvant chemotherapy for patients with muscle-invasive bladder cancer (MIBC). Patients were treated with Imfinzi in combination with neoadjuvant chemotherapy before cystectomy (surgery to remove the bladder) followed by Imfinzi as adjuvant monotherapy.\n \nApproximately one in four patients with bladder cancer has evidence of the tumour invading the muscle wall of the bladder (without distant metastases), known as MIBC.1,2 In the MIBC setting, approximately 117,000 patients are treated with current standard of care.3 Standard treatment includes neoadjuvant chemotherapy and radical cystectomy.4 However, even after cystectomy, patients experience high rates of recurrence and a poor prognosis.4\n \nProfessor Thomas Powles, MD, Professor, Director of Barts Cancer Centre (QMUL), London, UK, and investigator in the trial, said: \"Nearly half of patients with muscle-invasive bladder cancer who receive standard of care still experience disease recurrence or progression. These NIAGARA data show for the first time that adding durvalumab to chemotherapy before surgery followed by durvalumab extends patients' lives.\"\n \nSusan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca, said: \"The NIAGARA results support our strategy to move immunotherapy to the early stages of cancer treatment. This perioperative regimen with Imfinzi improved survival and reduced the rate at which patients experience disease recurrence or progression. We are eager to bring this regimen with the potential to transform the standard of care to patients as soon as possible.\"\n \nImfinzi was...